DOCSLIB.ORG

Sanitätsbetrieb Der Autonomen Provinz Bozen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sanitätsbetrieb Der Autonomen Provinz Bozen SANITÄTSBETRIEB DER AUTONOMEN PROVINZ BOZEN Anlage 2.a: Liste der entwickelten Projekte EVENTUELLE ZUKÜNFTIGE KOSTEN LAUFENDE KOSTEN INVESTITIONEN J A H R 2 0 1 7 J A H R 2 0 1 8 BEREICH BEGINN ENDE Kosten im Kosten im Abschrei- a) Krankenhaus Kosten für Güter Abschrei- GESAMT-KOSTEN DES Abschrei- Abschrei- Nr. Kurze Beschreibung des Projektes / Dienstes PROJEKT/ PROJEKT/ Sonstige Gesamte laufende Voranschlag Gesamtbetrag Voranschlag bungskosten GESAMT-KOSTEN GESAMT-KOSTEN b) Sprengel Personalkosten und Dienst- bungskosten JAHRES Laufende Kosten bungskosten Laufende Kosten bungskosten DIENST DIENST Kosten Kosten enthalten? Investition enthalten? sterilisiert? DES JAHRES DES JAHRES c) Prävention leistungen des Jahres des Jahres des Jahres JA / NEIN JA / NEIN JA / NEIN Projektleiter: Dr. Peer Robert 1 Umsetzung des Projektes Familienkrankenpflege Sprengel 2016 2018 408.682,00 € 408.682,00 € 408.682,00 € 1.256.807,93 € - € 1.256.807,93 € 2.575.137,93 € - € 2.575.137,93 € Projektleiter: Dr. Peer Robert 2 Prävention 2016 2018 17.637,15 € 5.062,78 € 22.699,93 € 22.699,93 € 100.000,00 € - € 100.000,00 € 100.000,00 € - € 100.000,00 € Diabetes Screening Projektleiter: Dr. Peer Robert 3 Sprengel 2016 2018 398.751,45 € 398.751,45 € 398.751,45 € 1.755.261,20 € - € 1.755.261,20 € 1.755.261,20 € - € 1.755.261,20 € Telemedizin für Patienten mit Diabetes Projektleiter: Dr. Armanaschi Luca 4 Projekt zum Auf- und Ausbau der Zertifizierung der Krankenhaus 854.448,40 € 56.516,00 € 910.964,40 € 110.940,00 € 1.021.904,40 € 954.448,30 € - € 954.448,30 € 954.448,39 € - € 954.448,39 € onkologischen Chirurgie Projektleiter: Dr.in Wachtler Bettina 5 Multidisziplinäres Zentrum für extrakorporale Krankenhaus 2016 2018 155.102,18 € 77.000,00 € 232.102,18 € 232.102,18 € 290.127,73 € - € 290.127,73 € 362.659,66 € - € 362.659,66 € Stoßwellentherapie Projektleiter: Dr. Mascheroni Donatella Krankenhaus / 6 2014 2017 90.521,91 € 11.228,32 € 101.750,23 € 101.750,23 € - € - € - € - € - € - € Unterstützung der Familien mit Migrationshintergrund Sprengel Projektleiter: Dr.in Siller Marianne 7 Krankenhaus 2016 2019 28.105,20 € 28.105,20 € 28.105,20 € 300.000,00 € - € 300.000,00 € 300.000,00 € - € 300.000,00 € Lean Healthcare Projektleiter: Prim. Dr. Saltuari Leopold 8 Krankenhaus 2015 2018 - € 56.448,00 € 56.448,00 € 56.448,00 € 56.448,00 € - € 56.448,00 € 56.448,00 € - € 56.448,00 € Forschung der Neuro-Reha Sterzing SUMME 1.925.143,09 € 234.360,30 € - € 2.159.503,39 € 110.940,00 € - € 2.270.443,39 € 4.713.093,16 € - € 4.713.093,16 € 6.103.955,18 € - € 6.103.955,18 € ND: nuovo servizio PM: progetto di modernizzazione /riordino o PSP NP: nuovo progetto 3P: progetto triennale Digital unterschriebenes2.a Projekte und gemäß den Gesetzesbestimmungen verwahrtes Dokument - Documento firmato digitalmente e conservato a norma di legge SANITÄTSBETRIEB DER AUTONOMEN PROVINZ BOZEN Gesundheitsbezirk Bozen Anlage 3.2.g: Leistungen von ausländischen Einrichtungen Beschreibung nicht-stationäre Leistungen Leistungsträger Patienten Betrag K.to Leistungen Patienten Betrag K.to (*) 410.100.40 (*) 410.200.40 TILAK - Universitätsklinik Innsbruck 393 4.551.343,85 16.613 1.211 797.231,05 Anstalten der Universitätsklinik Innsbruck - - 1.935 78 26.563,58 TILAK - Hochzirl - Natters 9 33.272,23 24 2 1.936,80 TILAK - Hall - - - - - Gemeinnützige Salzburger Landeskliniken 5 25.400,65 14 5 365,09 Psychiatrische Rehabilitation Bregenz - - - - - Allgemeine Unfallversicherungsanstalt 14 284.147,37 - - - Stiftung Maria Ebene 3 40.666,23 - - - Kurzzeittherapie "Haus am Seespitz" - - - - - Klinikum Augsburg 3 72.582,07 - - - Kinderklinik Garmisch-Partenkirchen 6 31.067,43 - - - Rheumaklinik Waldburg Zeil Oberammergau 59 123.998,14 - - - andere Einrichtungen - - 2.470 - 40.600,00 Insgesamt 492 5.162.477,97 21.056 1.296 866.696,52 (*) Anzahl der Zugänge Bozen Seite Nr. 1 Digital unterschriebenes und gemäß den Gesetzesbestimmungen verwahrtes Dokument - Documento firmato digitalmente e conservato a norma di legge SANITÄTSBETRIEB DER AUTONOMEN PROVINZ BOZEN Gesundheitsbezirk Meran Anlage 3.2.g: Leistungen von ausländischen Einrichtungen Beschreibung nicht-stationäre Leistungen Leistungsträger Patienten Betrag K.to Leistungen Patienten Betrag K.to (*) 410.100.40 (*) 410.200.40 TILAK - Universitätsklinik Innsbruck 435 3.486.726,65 13.599 425 518.956,17 Anstalten der Universitätsklinik Innsbruck - - 136 62 26.821,38 TILAK - Hochzirl - Natters 10 58.686,24 16 1 1.291,20 TILAK - Hall - - - - - Gemeinnützige Salzburger Landeskliniken 9 55.143,87 17 8 1.959,25 Psychiatrische Rehabilitation Bregenz - - - - - Allgemeine Unfallversicherungsanstalt 12 121.644,24 - - - Stiftung Maria Ebene 2 197.378,40 - - - Kurzzeittherapie "Haus am Seespitz" 9 38.824,11 - - - Klinikum Augsburg 2 60.102,71 - - - Kinderklinik Garmisch-Partenkirchen 5 8.177,59 - - - Rheumaklinik Waldburg Zeil Oberammergau 5 8.177,59 - - - andere Einrichtungen 20 42.911,96 - - - Insgesamt 504 4.069.595,75 15.276 496 573.828,00 (*) Anzahl der Zugänge Meran Seite Nr. 2 Digital unterschriebenes und gemäß den Gesetzesbestimmungen verwahrtes Dokument - Documento firmato digitalmente e conservato a norma di legge SANITÄTSBETRIEB DER AUTONOMEN PROVINZ BOZEN Gesundheitsbezirk Brixen Anlage 3.2.g: Leistungen von ausländischen Einrichtungen Beschreibung nicht-stationäre Leistungen Leistungsträger Patienten Betrag K.to Leistungen Patienten Betrag K.to (*) 410.100.40 (*) 410.200.40 TILAK - Universitätsklinik Innsbruck 322 2.670.810,26 15.042 471 531.975,94 Anstalten der Universitätsklinik Innsbruck - - 191 61 26.150,54 TILAK - Hochzirl - Natters 11 96.367,78 39 2 3.030,57 TILAK - Hall - - - - - Gemeinnützige Salzburger Landeskliniken 2 19.049,70 7 2 559,19 Psychiatrische Rehabilitation Bregenz - - - - - Allgemeine Unfallversicherungsanstalt 5 119.859,91 - - - Stiftung Maria Ebene - - - - - Kurzzeittherapie "Haus am Seespitz" - - - - - Klinikum Augsburg 5 77.058,69 - - - Kinderklinik Garmisch-Partenkirchen 3 12.456,31 - - - Rheumaklinik Waldburg Zeil Oberammergau 3 12.456,31 - - - andere Einrichtungen 5 13.635,58 - - - Insgesamt 353 3.009.238,22 16.058 536 574.516,23 (*) Anzahl der Zugänge Brixen Seite Nr. 3 Digital unterschriebenes und gemäß den Gesetzesbestimmungen verwahrtes Dokument - Documento firmato digitalmente e conservato a norma di legge SANITÄTSBETRIEB DER AUTONOMEN PROVINZ BOZEN Gesundheitsbezirk Bruneck Anlage 3.2.g: Leistungen von ausländischen Einrichtungen Beschreibung nicht-stationäre Leistungen Leistungsträger Patienten Betrag K.to Leistungen Patienten Betrag K.to (*) 410.100.40 (*) 410.200.40 TILAK - Universitätsklinik Innsbruck 463 3.410.439,93 17.229 1.527 706.551,73 Anstalten der Universitätsklinik Innsbruck - - 124 134 23.531,11 TILAK - Hochzirl - Natters 28 99.800,38 108 19 8.563,90 TILAK - Hall 1 8.204,64 - - - Gemeinnützige Salzburger Landeskliniken 1 16.041,85 3 1 204,55 Psychiatrische Rehabilitation Bregenz - - - - - Allgemeine Unfallversicherungsanstalt 13 287.861,43 - - - Stiftung Maria Ebene 1 42.209,78 - - - Kurzzeittherapie "Haus am Seespitz" 9 34.681,21 - - - Klinikum Augsburg 1 35.309,19 - - - Kinderklinik Garmisch-Partenkirchen - - - - - Rheumaklinik Waldburg Zeil Oberammergau - 26.236,60 - - - andere Einrichtungen 12 14.858,69 - - - Insgesamt 541 3.975.643,71 18.197 1.681 750.915,29 (*) Anzahl der Zugänge Bruneck Seite Nr. 4 Digital unterschriebenes und gemäß den Gesetzesbestimmungen verwahrtes Dokument - Documento firmato digitalmente e conservato a norma di legge SANITÄTSBETRIEB DER AUTONOMEN PROVINZ BOZEN Anlage 3.2.h stationäre Leistungen von vertragsgebundenen Einrichtungen im Lande Gesundheitsbetrieb Bozen Beschreibung stationäre Leistungen Patienten Betrag (**) Betrag (**) Struktur Art der Betreuung Betten Leistungen (*) 2016 2015 Villa S. Anna Akutmedizin 156 156 415.726,41 356.310,70 REHA und post-akute Villa Melitta 921 921 5.806.527,71 6.136.936,00 Langzeitkranke REHA und post-akute Bonvicini-Klinik 1.267 1.267 7.018.994,36 7.163.219,90 Langzeitkranke REHA und post-akute Martinsbrunn 19 19 104.354,14 110.557,89 Langzeitkranke REHA und post-akute Salus Center 362 362 1.429.261,65 - Langzeitkranke Villa S. Anna post-akute Langzeitkranke 19 19 97.691,00 121.466,40 Insgesamt Leistungen / Kosten 2.744 2.744 14.872.555,27 13.888.490,89 Gesundheitsbetrieb Meran Beschreibung stationäre Leistungen Patienten Betrag (**) Betrag (**) Struktur Art der Betreuung Betten Leistungen (*) 2016 2015 Villa S. Anna Akutmedizin 300 300 797.053,72 969.245,56 REHA und post-akute Villa Melitta 13 13 85.793,58 80.083,10 Langzeitkranke REHA und post-akute Bonvicini-Klinik 12 12 62.066,05 121.459,40 Langzeitkranke REHA und post-akute Martinsbrunn 413 413 2.670.370,88 2.602.605,40 Langzeitkranke REHA und post-akute Salus Center 447 447 1.874.691,75 - Langzeitkranke Villa S. Anna post-akute Langzeitkranke 303 303 2.005.137,20 1.872.489,30 Insgesamt Leistungen / Kosten 1.488 1.488 7.495.113,18 5.645.882,76 Gesundheitsbetrieb Brixen Beschreibung stationäre Leistungen Patienten Betrag (**) Betrag (**) Struktur Art der Betreuung Betten Leistungen (*) 2016 2015 Villa S. Anna Akutmedizin 2 2 3.680,04 10.824,63 REHA und post-akute Villa Melitta 7 7 78.380,23 49.182,10 Langzeitkranke REHA und post-akute Bonvicini-Klinik 2 2 13.417,80 32.981,83 Langzeitkranke REHA und post-akute Martinsbrunn 3 3 13.598,48 2.428,30 Langzeitkranke REHA und post-akute Salus Center 24 24 115.414,88 - Langzeitkranke Villa S. Anna post-akute Langzeitkranke 1 1 7.062,00 - Insgesamt Leistungen / Kosten 39 39 231.553,43 95.416,86 Gesundheitsbetrieb Bruneck Beschreibung stationäre
Load more

Recommended publications
  • (201 1.01) A61k 31/713
    ( (51) International Patent Classification: S McAllister Ave., Tempe, Arizona 85281 (US). ZHANG, C12N 15/11 7 (20 10.01) B82Y 5/00 (201 1.01) Fei; 5460 S Scott PI, Chandler, Arizona 85249 (US). A61K 31/713 (2006.01) C12N 15/115 (2010.01) (74) Agent: NORTON, Vicki G.; DUANE MORRIS LLP, 750 A61K 39/39 (2006.01) B Street, Suite 2900, San Diego, California 92101-4681 (21) International Application Number: (US). PCT/U S201 9/013 118 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection av ailable) . AE, AG, AL, AM, 10 January 2019 (10.01.2019) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/615,806 10 January 2018 (10.01.2018) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: ARIZONA BOARD OF REGENTS ON BE¬ SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, HALF OF ARIZONA STATE UNIVERSITY [US/US]; TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1475 North Scottsdale Road, SkySong - Suite 200, Scotts¬ (84) Designated States (unless otherwise indicated, for every dale, Arizona 85257-3538 (US).
    [Show full text]
  • R&D Briefing 76
    The Impact of Recent Regulatory Developments on the Mexican Therapeutic Landscape Access to innovative medicines is key to El acceso a medicamentos innovadores es clave para improving overall population health, reducing mejorar la salud de toda la población, para reducir los hospitalisation time and decreasing morbidity and tiempos de hospitalización, la morbilidad y la mortalidad mortality. An efficient regulatory process can be de un país. Un proceso regulatorio eficiente tiene un reflected in measurable positive health impacts; impacto positivo medible en la salud, y por el contrario, conversely, activities that slow or impede acciones que retrasan o impiden la eficiencia regulatoria y regulatory efficiency and predictability can be su predictibilidad pueden ser perjudiciales. La parálisis detrimental. Recent developments in the Mexican reciente del Sistema regulatorio mexicano respecto a la regulatory system for the assessments of evaluación de nuevos medicamentos innovadores innovative new products have had a negative conlleva un impacto negativo en la salud de la población impact on Mexican public health. mexicana. This Briefing addresses the impact of suspending Este informe analiza el impacto de la suspensión de las the activities of the New Molecules Committee actividades del Comité de Moléculas Nuevas (NMC, por (NMC) on the Mexican therapeutic landscape. sus siglas en inglés) sobre el horizonte terapéutico de First, we compared the way that “new medicines” México. En primer lugar, comparamos la definición de are defined within the context of the Mexican nuevos medicamentos según el contexto regulatorio regulatory system, with definitions used by mexicano con las definiciones adoptadas por otras comparable regulators and health organisations. agencias reguladoras u organizaciones de salud del We have also investigated the extent to which mundo.
    [Show full text]
  • Renal Clinical Pharmacy Services“
    DISSERTATION „Renal clinical pharmacy services“ Mag.pharm. Gunar Stemer angestrebter akademischer Grad Doktor der Naturwissenschaften (Dr.rer.nat.) Wien, 2011 Studienkennzahl lt. Studienblatt: A 091 449 Dissertationsgebiet lt. Studien- Pharmazie blatt: Betreuerin / Betreuer: Ao. Univ. Prof. Mag. Dr. Rosa Lemmens 2 e pensando di lei mi sopragiunse uno soave sonno ego dominus tuus vide cor tuum e d’esto core ardendo cor tuum lei paventosa umilmente pascea appreso gir io ne vedea piangendo la letizia si convertia in amarissimo pianto io sono in pace cor meum io sono in pace vide cor meum Dante Alighieri La Vita Nuova ~1293 Gewidmet meinen Eltern Annelies und Franz, in aufrichtiger Dankbarkeit und Liebe Dedicated to my parents Annelies and Franz, in sincere gratitude and love 3 4 ACKNOWLEDGEMENTS This thesis would not have been possible without the continuous support, help, and contributions of so many colleagues, companions, friends, and beloved family members. First, I want to express my deepest gratitude to my doctoral advisor, Mrs. Prof. Rosa Lemmens, for her commitment in supervising my thesis work, her support during the writing of this thesis, several constructive discussions with her, and her critical comments. My sincerest thanks are extended to the head of the pharmacy department of the Vienna General Hospital, Mrs. SR Mag. Elfriede Dolinar, for providing me with this unique opportunity to work on the topic of clinical pharmacy and, thus, contribute to the evolution of the complete hospital pharmacy and clinical pharmacy discipline in Austria. I would like to thank her for her trust in my capabilities to succeed in this demanding project over the last three years by implementing new services, her vision regarding the discipline of hospital pharmacy, her overall contribution to the development of the profession of hospital pharmacy, and her continuous belief in the value of clinical pharmacy services.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Etoposide ”Ebewe ” 20 mg/ml – Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 20 mg of etoposide. 1, 5, or 10 vials of 2.5 ml concentrate for solution for infusion contains 50 mg etoposide. 1, 5, or 10 vials of 5 ml concentrate for solution for infusion contains 100 mg etoposide. 1, 5, or 10 vials of 10 ml concentrate for solution for infusion contains 200 mg etoposide. 1, 5, or 10 vials of 20 ml concentrate for solution for infusion contains 400 mg etoposide. 1, 5, or 10 vials of 50 ml concentrate for solution for infusion contains 1000 mg etoposide. Excipients: Benzyl alcohol, ethanol. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, light yellow solution. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Etoposide is a antineoplastic agent for intravenous use. It can be used alone or in combination with other oncolytic agents. Available data show that etoposide may be used in treatment of small -celled lung cancer, resistant non -seminomatous testicular carcinoma, acute myelomonocytic and myelocytic leukaemia (AML, FAB subtype M4 or M5) as part of combination therapy after failure of induction chemotherapy. 4.2 Posology and method of administration Etoposide should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents. Pregnant personnel should not handle chemotherapeutic agents.
    [Show full text]
  • Aspects of the Usage of Antineoplastic and 1Mmunomodulating Agents in a Section of the Private Health Care Sector
    ASPECTS OF THE USAGE OF ANTINEOPLASTIC AND 1MMUNOMODULATING AGENTS IN A SECTION OF THE PRIVATE HEALTH CARE SECTOR Wilmarie Rheeders B. Pharm Dissertation submitted in Pharmacy Practice, School of Pharmacy at the Faculty of Health Sciences of the North-West University, Potchefstroom, in partial fulfilment of the requirements for the degree Magister Pharmaciae. Supervisor: Prof M.S. Lubbe Co-supervisor: Dr. J.L. Duminy Co-supervisor: Prof. M.P. Stander Potchefstroom November 2008 For all things are from Him, by Him, and for Him. Glory belongs to Him forever! Amen. (Rom. 11:36) ACKNOWLEDGEMENTS To my Lord and Father whom I love, all the Glory! He gave me the strength, insight and endurance to finish this study. 1 also want to express my sincere appreciation to the following people that have contributed to this dissertation: • To Professor M.S. Lubbe, in her capacity as supervisor of this dissertation, my appreciation for her expert supervision, advice and time she invested in this study. • To Dr. J.L Duminy, oncologist and co-supervisor, for all the useful advice, assistance and time he put aside in the interest of this dissertation. • To Professor M.P. Stander, in his capacity as co-supervisor of this study. • To Professor J.H.P. Serfontein, for his guidance, time, effort and advice. • To the Department of Pharmacy Practice as well as the NRF for the technical and financial support. • To Anne-Marie, thank you for your patience, time and continuous effort you put into the data. • To the Pharmacy Benefit Management company for providing the data for this dissertation.
    [Show full text]
  • ORG Medicamentos Alto Impacto Econo Mico Maquetaciûn 1
    Rev. OFIL·ILAPHAR 2020 [first on line] / ORIGINAL / 1 Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalaria FORTES-GONZÁLEZ MS, VAZQUEZ-BLANCO S, HERRERO-POCH L, DE MIGUEL-BOUZAS JC, CASTRO-DOMÍNGUEZ JM, VILLAMAYOR-BLANCO L Servicio de Farmacia Hospitalaria. Hospital Povisa. Vigo (España) Fecha de recepción: 19/10/2020 - Fecha de aceptación: 24/11/2020 RESUMEN los MAC fueron innovadores, 26,5% huérfanos y 34,0% Objetivos: Los medicamentos de alto impacto económico biológicos. Dieciséis medicamentos tuvieron un coste (MAIE) constituyen un reto para los servicios de salud pú- >10.000 €/envase. Los MEC pertenecieron principalmente blicos de los países europeos. Sin embargo, no existe con- al grupo L (45,0%) y J (35,0%). El PVL medio diario de los senso sobre qué constituye un MAIE. El objetivo del estudio MEC fue 154,4 € (1,1-1.629,3). El 35,5% fueron innova- fue configurar una lista de MAIE dispensados por los servi- dores, 5,0% huérfanos y 60,0% biológicos. cios de farmacia hospitalarios y analizar la situación respecto Conclusiones: Un elevado número de MAIE son dispensados a estos fármacos en España. por los servicios de farmacia hospitalarios, principalmente Métodos: Se consideraron MAIE aquellos fármacos con un antineoplásicos y antiinfecciosos. Aunque el PVL mínimo coste >10.000 €/año (MAC) o con un elevado volumen de diario para considerar un medicamento de alto impacto es consumo (MEC). Se estimaron los precios (PVL) por dosis 27,4 €, el PVL medio diario de los MAC fue >200 €. Sin diaria definida o dosis diaria prescrita. embargo, el elevado consumo de algunos fármacos, hace Resultados: Un total de 147 principios activos fueron consi- que medicamentos con un coste tan bajo como 1,1 € pue- derados MAC, correspondiendo mayoritariamente con los dan ser considerados MAIE.
    [Show full text]
  • ORG Medicamentos Alto Impacto Econo Mico Maquetaciûn 1
    Rev. OFIL·ILAPHAR 2020 [first on line] / ORIGINAL / 1 Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalaria FORTES-GONZÁLEZ MS, VAZQUEZ-BLANCO S, HERRERO-POCH L, DE MIGUEL-BOUZAS JC, CASTRO-DOMÍNGUEZ JM, VILLAMAYOR-BLANCO L Servicio de Farmacia Hospitalaria. Hospital Povisa. Vigo (España) Fecha de recepción: 19/10/2020 - Fecha de aceptación: 24/11/2020 RESUMEN los MAC fueron innovadores, 26,5% huérfanos y 34,0% Objetivos: Los medicamentos de alto impacto económico biológicos. Dieciséis medicamentos tuvieron un coste (MAIE) constituyen un reto para los servicios de salud pú- >10.000 €/envase. Los MEC pertenecieron principalmente blicos de los países europeos. Sin embargo, no existe con- al grupo L (45,0%) y J (35,0%). El PVL medio diario de los senso sobre qué constituye un MAIE. El objetivo del estudio MEC fue 154,4 € (1,1-1.629,3). El 35,5% fueron innova- fue configurar una lista de MAIE dispensados por los servi- dores, 5,0% huérfanos y 60,0% biológicos. cios de farmacia hospitalarios y analizar la situación respecto Conclusiones: Un elevado número de MAIE son dispensados a estos fármacos en España. por los servicios de farmacia hospitalarios, principalmente Métodos: Se consideraron MAIE aquellos fármacos con un antineoplásicos y antiinfecciosos. Aunque el PVL mínimo coste >10.000 €/año (MAC) o con un elevado volumen de diario para considerar un medicamento de alto impacto es consumo (MEC). Se estimaron los precios (PVL) por dosis 27,4 €, el PVL medio diario de los MAC fue >200 €. Sin diaria definida o dosis diaria prescrita. embargo, el elevado consumo de algunos fármacos, hace Resultados: Un total de 147 principios activos fueron consi- que medicamentos con un coste tan bajo como 1,1 € pue- derados MAC, correspondiendo mayoritariamente con los dan ser considerados MAIE.
    [Show full text]
  • Wo 2007/073499 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 28 June 2007 (28.06.2007) WO 2007/073499 A2 (51) International Patent Classification: Not classified BRUCKHEIMER, Elizabeth [US/US]; 4312 Frankfort (21) International Application Number: Drive, Rockville, MD 20853 (US). SCHLERETH, PCT/US2006/048995 Bernd [DE/DE]; Keltenstr. 13, 821 10 Germering (DE). HAMMOND, Scott, A. [US/US]; 3216 Llewellyn Field (22) International Filing Date: Road, Olney, MD 20832 (US). LUTTERBUESE, RaIf 2 1 December 2006 (21.12.2006) [DE/DE]; Fliederstr. 11, 82061 Neuried (DE). KIENER, (25) Filing Language: English Peter, A. [US/US]; 1017 Gorky Drive, Potomac, MD (26) Publication Language: English 20854 (US). BAEURELE, Patrick [DE/DE]; Waldprom- enade 18c, 82131 Gauting (DE). LUTTERBUESE, Petra (30) Priority Data: [DE/DE]; Fliederstr. 11, 82061 Neuried (DE). 60/753,368 2 1 December 2005 (21.12.2005) US (71) Applicants (for all designated States except US): MED- (74) Agents: INSOGNA, Anthony M. et al; Jones Day, 222 IMMUNE, INC. [US/US]; One Medimmune Way, East 41st Street, New York, NY 10017-6702 (US). Gaithersburg, MD 20878 (US). MICROMET AG (81) Designated States (unless otherwise indicated, for every [DE/DE]; Staffelseestr. 2, 81477 Munich (DE). kind of national protection available): AE, AG, AL, AM, (72) Inventors; and AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (75) Inventors/Applicants (for US only): KINCH, Michael, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FT, S. [US/US]; 19627 Hoover Farm Drive, Laytonsville, MD GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, 20883 (US).
    [Show full text]
  • International Price Comparison of Pharmaceuticals 2017
    International price comparison of pharmaceuticals 2017 – a volume based analysis of Swedish pharmaceutical prices and volumes relative to 19 other European coun- tries. 2 (101) You are welcome to quote Dental and Pharmaceutical Benefits Agency reports, but please remember to cite the source: the report’s name, year and Dental and Phar- maceutical Benefits Agency. Dental and Pharmaceutical Benefits Agency, February 2018 Authors: Emil Aho, Pontus Johansson and Gunilla Rönnholm. Reference number: 3611/2017 Postal address: Box 22520, 104 22 Stockholm Visiting address: Fleminggatan 18, Stockholm Telephone: +46 8 568 420 50 www.tlv.se 3 (101) Preface The Dental and Pharmaceutical Benefits Agency’s (TLV’s) mandate includes moni- toring and analysing the price development of pharmaceuticals from an interna- tional perspective. In this report, TLV presents the results of the analysis of price and volume data for the first quarter of 2014, 2015, 2016 and 2017 in Sweden in comparison with 19 other European countries. The segments analysed are pharmaceuticals not exposed to competition and pharmaceuticals exposed to competition, with the latter includ- ing all pharmaceuticals available as substitutable medicines in the product-of-the- month system as per March 2017. The report should be viewed as a basis for further analysis of the dynamics of Swe- dish prices and price changes compared to that seen internationally. Sofia Wallström Director-General 4 (101) 5 (101) Table of contents Preface ..................................................................................................................
    [Show full text]
  • A Plea to Systematically Assess the Real-World Cost-Effectiveness Of
    Erasmus Universiteit Rotterdam Handling uncertainty: a plea to systematically assess the real-world cost-effectiveness of expensive outpatient medicines Cost-effectiveness review and critical evidence appraisal for pharmaceutical products potentially benefitting most from unrevised reimbursement in the Netherlands Frank G. Sandmann [Rotterdam, November 2011] - i - A thesis submitted to the Institute of Health Policy and Management at the Erasmus University Rotterdam, the Netherlands, in partial fulfilment of the requirements for the degree of Master of Science in Health Economics, Policy and Law with a specialisation in ‘ Health Economics ’. Rotterdam, 30 November 2011 Thesis Supervisor Dr. Marc Koopmanschap – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Co-Readers Prof. dr. Adri Steenhoek – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Dr. Ken Redekop – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Frank Gerd Sandmann Student of Health Economics (349997) Institute of Health Policy and Management (iBMG) & Erasmus School of Economics (ESE) Erasmus University Rotterdam, Rotterdam, The Netherlands - ii - Dedication Gewidmet meinen Großeltern Margret und Josef Feilen. - iii - Acknowledgements I would like to thank my daily supervisor Marc Koopmanschap for his comments, expertise, and kind supportive attitude. You truly mastered the ‘open-door’ policy and I always felt good taken care of. A positive outlook on life can make a lot look so much easier than expected. I also highly value the effort from Wil Toenders for his comments on a preliminary concept version of the text parts for the two medications imatinib and pegfilgrastim. I would like to thank Adri Steenhoek and Margreet Franken. Our work was inspiration for me and this thesis! My great sense of appreciation goes to my friends Clare Ninsiima, René Miller, and Ilja Löwen.
    [Show full text]
  • Utilization and Expenditure of Anti-Cancer Medicines in Kosovo: Findings and Implications
    PharmacoEconomics Open (2018) 2:423–432 https://doi.org/10.1007/s41669-017-0066-8 ORIGINAL RESEARCH ARTICLE Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications 1,2 3,4,5 5 5 Arianit Jakupi • Brian Godman • Antony Martin • Alan Haycox • Indrit Baholli6 Published online: 2 February 2018 Ó The Author(s) 2018. This article is an open access publication Abstract Method National drug utilization data is available in Background and Objective The Ministry of Health (MoH) Kosovo. Utilization and expenditure on anti-cancer leads and organizes health policy in Kosovo, which medicines [Anatomical Therapeutic Chemical (ATC) code includes procurement and provision of medicines, includ- L], initially from 2011 to 2013, especially for anti-cancer ing anti-cancer medicines, which compose a special group medicines on the essential medicines list was analysed of medicines. However, there has been limited analysis of from national data. In addition, current systems for the utilization and expenditure on anti-cancer medicines in procuring and managing anti-cancer medicines in Kosovo Kosovo; consequently, the objective of this study is to was documented. undertake research to provide future guidance on the use of Results There was appreciable variability in the utilization anti-cancer medicines. of anti-cancer medicines over the years, with low or limited use of some anti-cancer medicines on the Essential Medi- cine List. This is a concern in view of their essential & Brian Godman medicine status. From 2011 to 2013, €16.49 million was [email protected]; [email protected]; spent on anti-cancer medicines (ATC L).
    [Show full text]